BioTuesdays

Category - Features

Knight won’t rest til it bests Paladin

“It is entirely the goal of Knight Therapeutics (TSX:GUD) to duplicate the success of Paladin Labs,” says president and CEO, Jonathan Ross Goodman, who turned Paladin into a premier distributor of specialty drugs...

In conversation with Alistair Duncan

As a co-founder, president and CEO of closely held viDA Therapeutics, a tissue repair company, Alistair Duncan has developed an affinity for doing biotech startups. From 1998 to 2008, he was president and CEO of Chromos...

Transition moves into late-stage drug development

Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has added late-stage drug development to its operations with its acquisition from Perrigo plc (NYSE, TASE:PRGO) of neuropsychiatric drug candidate, ELND005. “We’re maybe a...

Alpha Cancer to test oncology game changer

Closely held Alpha Cancer Technologies, which is going public in a reverse takeover of Bradmer Pharmaceuticals (TSX-V:BMR-H), plans to begin testing patients with ovarian cancer this year with its drug candidate, ACT...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.